BPC-157
Reported Onset
1–2 weeks
Primary Use
Accelerated tendon, ligament, and gut tissue repair.
Dose
250mcg - 500mcg
Frequency
1-2x daily
ARA-290
Reported Onset
2–4 weeks
Primary Use
Tissue protection, neuropathy relief, and anti-inflammatory action.
Dose
4mg - 8mg
Frequency
Daily
Community Verdict
Both tissue protective; ARA-290 targets neuropathy, BPC-157 targets structural repair. The community generally selects between BPC-157 and ARA-290 based on their specific goals and experience. Both compounds are available through physician-supervised protocols at Alukard, where a physician can help determine which is most appropriate for your situation.
Get a Physician-Supervised Protocol for BPC-157 or ARA-290 at Alukard
Community experiences are a starting point — but a physician-supervised protocol from Alukard gives you pharmaceutical-grade compounds, proper dosing, lab monitoring, and the safety of medical oversight.
MD
Supervised
GMP
Certified
Labs
Monitoring
COA
Verified